In 2021, the Department of Health Government of Australia supported the public funding of TMVr by edge-to-edge repair/tissue approximation using the MitraClip™ system (Abbott Structural, Santa Clara, CA, USA) in patients with moderate-severe or severe symptomatic degenerative (or primary) MR and left ventricular ejection fraction (LVEF) ≥20% who are determined by a Heart Team to be ineligible for surgical intervention.
Operators and institutions performing transcatheter mitral valve interventions will be formally recognised by the Transcatheter Mitral Valve Therapies (TMVT) Accreditation Committee, a committee of Cardiac Accreditation Services Ltd.
The TMVT Committee comprises cardiologists and cardiothoracic surgeons as representatives of the Cardiac Society of Australia and New Zealand (CSANZ) and the Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS).
Applicants need to be accredited for each site at which the TMVr procedure is performed. Applicants need to ensure that each site meets required institutional criteria.